Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.408
EU - Europa 3.448
AS - Asia 1.663
SA - Sud America 11
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 11.550
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.335
IT - Italia 1.078
SG - Singapore 734
DE - Germania 582
IE - Irlanda 499
SE - Svezia 387
CN - Cina 382
RU - Federazione Russa 381
HK - Hong Kong 244
ID - Indonesia 139
GB - Regno Unito 115
UA - Ucraina 114
CA - Canada 70
FI - Finlandia 60
AT - Austria 56
IN - India 56
DK - Danimarca 53
VN - Vietnam 45
FR - Francia 35
NL - Olanda 27
TR - Turchia 21
BE - Belgio 14
ES - Italia 9
JP - Giappone 9
IR - Iran 8
RO - Romania 6
BR - Brasile 5
CH - Svizzera 5
CL - Cile 5
CZ - Repubblica Ceca 5
SC - Seychelles 5
EU - Europa 4
KR - Corea 4
PK - Pakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
AU - Australia 3
BG - Bulgaria 3
LT - Lituania 3
PH - Filippine 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
MU - Mauritius 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CR - Costa Rica 1
EC - Ecuador 1
ET - Etiopia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PL - Polonia 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 11.550
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.733
Singapore 652
Fairfield 506
Dublin 487
Frankfurt am Main 451
Chandler 367
Milan 354
Wilmington 344
Woodbridge 305
Ashburn 287
Houston 247
Hong Kong 240
New York 231
Santa Clara 215
Seattle 196
Cambridge 183
Princeton 160
Jakarta 139
Jacksonville 109
Dearborn 86
Lawrence 74
Altamura 72
Shanghai 56
San Diego 52
Vienna 52
Chicago 44
Guangzhou 41
Beijing 40
Helsinki 37
Rome 36
London 34
Nanjing 34
Andover 33
Boardman 32
Dong Ket 27
Lissone 22
Falls Church 21
Toronto 21
Pune 19
Desio 18
Kocaeli 17
Hebei 16
Monza 15
Ottawa 15
Brussels 14
Lachine 14
Tianjin 14
Hangzhou 13
Jinan 13
Carate Brianza 12
Edmonton 12
Turin 11
Florence 10
Munich 10
Nanchang 10
Norwalk 10
Zhengzhou 10
Amsterdam 9
Council Bluffs 9
Los Angeles 9
Paris 9
Kunming 8
Lappeenranta 8
Redmond 8
Romola 8
Shenyang 8
Cinisello Balsamo 7
Potenza 7
Shenzhen 7
Chengdu 6
Dallas 6
Hyderabad 6
Lecco 6
Modena 6
Torre Del Greco 6
Washington 6
Wuhan 6
Atlanta 5
Bergamo 5
Bologna 5
Capaccio 5
Cassano Magnago 5
Changsha 5
Ferrara 5
Fremont 5
Genoa 5
Hounslow 5
Islington 5
Legnano 5
Marietta 5
Moscow 5
Mumbai 5
Palermo 5
Upper Marlboro 5
Brescia 4
Casalecchio di Reno 4
Edinburgh 4
Esslingen am Neckar 4
Leawood 4
Madrid 4
Totale 8.527
Salva come PNG Salva come JPEG
Nome #
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 405
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 310
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 305
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 253
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 242
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 239
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 237
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 233
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 230
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 222
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 216
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 205
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 199
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 198
A second update on mapping the human genetic architecture of COVID-19 194
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 190
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 188
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 183
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 178
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 169
Mapping the human genetic architecture of COVID-19 169
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 165
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 157
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 152
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 148
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 148
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 146
When progressive dysphagia could be related to an “old friend” – a case report 144
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 143
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 141
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 136
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 131
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 129
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 129
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 127
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 120
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 118
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 117
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 116
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 115
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 115
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 115
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 113
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 112
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 111
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 105
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 104
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 102
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 102
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 101
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 101
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 100
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 92
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 87
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 85
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 84
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 84
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 84
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 84
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 81
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 78
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 78
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 75
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 74
Adjuvant systemic treatment of early breast cancer: the NORA study 71
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 71
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 69
In reply to Kadri Altundag 68
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study 66
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 66
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study 65
Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations 63
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 63
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 62
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 62
5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study 60
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 60
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 59
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 58
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study 57
Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? 56
Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting 55
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab 54
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials 53
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 52
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 51
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 49
Metronomic chemotherapy for advanced breast cancer patients 46
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study 45
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 45
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 45
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 44
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development 44
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 44
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 43
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 43
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study 43
Metronomic chemotherapy 42
Gene expression profiling in breast cancer: a clinical perspective 41
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 40
Totale 11.569
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.005 0 0 0 0 0 94 225 212 192 124 128 30
2020/20212.513 71 208 212 204 184 236 223 359 240 210 175 191
2021/20221.198 126 121 150 87 49 90 62 89 58 75 85 206
2022/20232.072 252 550 162 154 121 268 132 128 96 61 82 66
2023/20241.908 81 74 65 91 251 392 345 57 167 56 65 264
2024/20252.278 251 743 411 257 368 248 0 0 0 0 0 0
Totale 12.248